Sarepta Therapeutics, Inc. and TG Therapeutics, Inc.: A Comprehensive Revenue Analysis

Biotech Revenue Surge: Sarepta vs. TG Therapeutics

__timestampSarepta Therapeutics, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 20149757000152381
Thursday, January 1, 20151253000152381
Friday, January 1, 20165421000152381
Sunday, January 1, 2017154584000152381
Monday, January 1, 2018301034000152000
Tuesday, January 1, 2019380833000152000
Wednesday, January 1, 2020540099000152000
Friday, January 1, 20217018870006689000
Saturday, January 1, 20229330130002785000
Sunday, January 1, 20231243336000233662000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Sarepta Therapeutics, Inc. and TG Therapeutics, Inc. have showcased contrasting revenue trajectories. Sarepta Therapeutics has experienced a remarkable surge, with revenue increasing by over 12,600% from 2014 to 2023. This growth highlights Sarepta's strategic advancements in gene therapy and muscular dystrophy treatments. In contrast, TG Therapeutics, Inc. saw a modest revenue increase, with a significant jump in 2023, marking a pivotal year with a 9,000% rise compared to 2022. This leap suggests a breakthrough in their therapeutic offerings. The data underscores the importance of innovation and market adaptation in the biotech sector, where a single year can redefine a company's financial landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025